Evidence map›Paper›PMID 41490873›Full record

ArticleNeurobiology of disease2026

Chemogenetic activation of hippocampal area CA2 promotes acute and chronic seizures in a mouse model of epilepsy.

John J LaFrancois, Meghan Kennedy, Monarchsinh Rathod, Bina Santoro, Christos Panagiotis Lisgaras, Steven A Siegelbaum, Helen E Scharfman

Abstract read
In one paragraph

Article in Neurobiology of disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

John J LaFrancoisThe Nathan Kline Institute of Psychiatric Research, Orangeburg, NY 10962, United States of America.
Meghan KennedyThe Nathan Kline Institute of Psychiatric Research, Orangeburg, NY 10962, United States of America.
Monarchsinh RathodThe Nathan Kline Institute of Psychiatric Research, Orangeburg, NY 10962, United States of America.
Bina SantoroDepartment of Neuroscience, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, United States of America.
Christos Panagiotis LisgarasThe Nathan Kline Institute of Psychiatric Research, Orangeburg, NY 10962, United States of America; Departments of Child & Adolescent Psychiatry, Neuroscience & Physiology, and Psychiatry and the Neuroscience Institute, New York University Grossman School of Medicine, New York, NY 10016, United States of America.
Steven A SiegelbaumDepartment of Neuroscience, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, United States of America.
Helen E ScharfmanThe Nathan Kline Institute of Psychiatric Research, Orangeburg, NY 10962, United States of America; Departments of Child & Adolescent Psychiatry, Neuroscience & Physiology, and Psychiatry and the Neuroscience Institute, New York University Grossman School of Medicine, New York, NY 10016, United States of America. Electronic address: helen.scharfman@nki.rfmh.org.

Funding

The Role of Hippocampal area CA2 in EpilepsyR01NS106983 · NINDS · NATHAN S. KLINE INSTITUTE FOR PSYCH RES · PI Helen E Scharfman · 2018 to 2026
$4.9M
NINDS NIH HHS R01 NS106983
6 · The paper itself

Abstract

Pyramidal cells (PCs) of hippocampal area CA2 exhibit increased excitability in temporal lobe epilepsy (TLE) and in mouse models of TLE. In epileptic mice, selective inhibition of CA2 PCs reduces chronic seizures. Here we asked if activating CA2 PCs increases seizures. Mice expressing Cre recombinase in CA2 PCs (Amigo2-Cre mice) were injected with the convulsant pilocarpine to induce a period of severe seizures (status epilepticus, SE), which leads to chronic seizures after 3-4 weeks (epilepsy). Epileptic mice were injected with a Cre-dependent adeno-associated virus (AAV) to express an excitatory designer receptor exclusively activated by designer drug (eDREADD; hM3Dq) in dorsal CA2 bilaterally and implanted with subdural EEG electrodes. After recovery, mice were recorded continuously using video and EEG for 6 weeks, 3 weeks with drinking water containing the eDREADD activator clozapine-N-oxide (CNO) and 3 weeks without CNO. CA2 activation with CNO caused a significant increase in seizure frequency and duration. Seizures occurred in clusters (many seizures per day over several consecutive days) and mice given water with CNO had a greater maximum number of seizures per day during a cluster compared to water without CNO. CNO had no significant effect in control mice. In naïve Amigo2-Cre mice expressing hM3Dq, pre-treatment with CNO before pilocarpine administration shortened the latency to SE and increased EEG power at the start of SE. Taken together with prior findings, the results suggest that CA2 is a control point for regulating seizures in the pilocarpine mouse model of TLE.

Indexed as

CA2 Region, HippocampalEpilepsySeizuresAnimalsChemogeneticsClozapineDisease Models, AnimalElectroencephalographyEpilepsy, Temporal LobeMaleMiceMice, Inbred C57BLMice, TransgenicPilocarpinePyramidal CellsClozapineclozapine N-oxidePilocarpineDesigner receptors exclusively activated by designer drugs (DREADDs)Electroencephalogram (EEG)PilocarpineSeizureSex differencesStatus epilepticus (SE)Temporal lobe epilepsy (TLE)

Identifiers

PMID41490873
PMCPMC12884373

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.